Gilead raises 2026 sales outlook amid acquisition costs
Gilead raised its 2026 sales outlook on strong HIV drug results but expects an annual loss due to acquisition costs. Quarterly earnings beat analyst estimates.
Xurve View
Insights:
Xurve View
GILEAD SCIENCES INC raised its 2026 sales forecast to $30.4 billion despite projecting an annual loss from recent acquisition costs. The drugmaker increased its estimate for HIV prevention drug Yeztugo sales to $1 billion from a previous $800 million. Strong HIV portfolio growth offsets a projected $0.65 to $1.05 per share loss tied to three biotech acquisitions.
